On June 24, 2026, a roster that includes ARCH Venture Partners, a16z Bio+Health, Blackstone Multi-Asset Investing, Canada Pension Plan Investment Board, RA Capital Management, T. Rowe Price, and a newly added co-lead in TCGX put $330 million into a single pre-Phase 3 ophthalmology asset. The round did not just close. It oversubscribed. In a year when ophthalmology venture has been selective, that word carries weight.
Ollin Biosciences is advancing OLN324 (co-developed with Innovent Biologics as IBI324), a VEGF/Ang-2 bispecific antibody, into global Phase 3 studies in both diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), with trials commencing in the second half of 2026. The target of those trials is implicit in the capital stack: Roche’s faricimab (Vabysmo), the current dual-mechanism standard that already dethroned aflibercept as the leading conversation in retinal disease. Ollin ran a randomized, head-to-head Phase 1b study called JADE directly against faricimab in both DME and wet AMD. The investors read those results, and then they wrote the check anyway. That sequence matters.
The Old Playbook No Longer Works
Until recently, the strategic consensus in retinal disease was straightforward: beat aflibercept on dosing interval, capture the ophthalmologist’s calendar, win market share. Roche broke that consensus when faricimab demonstrated that dual blockade of both VEGF-A and Angiopoietin-2 could address vascular leakage and neovascularization through distinct, complementary pathways — offering durability that a single-axis agent structurally cannot match. The market shifted its expectation: the next-generation standard would need a dual mechanism, not just a longer half-life.
That reframe is now encoded in the capital markets. The DME market alone was valued at $6.70 billion in 2024 and is projected to reach $11.02 billion by 2034, according to Research and Markets. Wet AMD carried a separate and larger commercial footprint: anti-VEGF drugs captured 67.3% of the wet AMD market in 2025, valued at $12.39 billion, with aflibercept still holding the largest individual share at 35.7%. But aflibercept’s dominance is a lagging indicator. The forward question is whether faricimab’s dual-mechanism thesis can itself be out-executed — and that is precisely the bet Ollin is making.
Investors are no longer pricing the anti-VEGF monotherapy era. They are pricing the post-faricimab era, and they decided OLN324 is the most credible early ticket into that window.
Who Absorbs the Pressure
Roche carries the most immediate exposure. Faricimab launched as the first Ang-2/VEGF bispecific approved for retinal disease, and its commercial identity is built on being the dual-mechanism pioneer. A Phase 3-ready competitor with head-to-head data from a randomized study, backed by $330 million and a global trial infrastructure through Innovent’s China operations, compresses Roche’s window to establish durable switching inertia. Every quarter that OLN324 advances in Phase 3 is a quarter that hospital formulary committees, payers, and retinal specialists have reason to pause a long-term faricimab commitment.
Regeneron and Bayer face a different kind of pressure. Their high-dose aflibercept strategy (Eylea HD, approved in 2023) positioned extended dosing intervals as the counter-narrative to faricimab’s dual mechanism. OLN324’s advancement validates the market’s appetite for mechanism differentiation over dosing convenience alone, which structurally disadvantages a single-axis, higher-dose approach. If Phase 3 OLN324 data replicates or extends the JADE signal against faricimab, aflibercept’s lifecycle management thesis weakens further.
The clearer beneficiaries sit at the platform level. Innovent Biologics holds the China rights and co-development economics on IBI324, and a $330 million oversubscribed round de-risks the Phase 3 execution substantially on Ollin’s side of the ledger. For Innovent, this is a capital-light path to a potential best-in-class position in a Chinese retinal disease market where faricimab has not yet fully consolidated. ARCH Venture Partners, which participated as a founding investor and returned for the Series B, gets the carried-interest math that comes with leading the defining retinal deal of this funding cycle.
The Signal Beneath the Signal
If you are running business development at a mid-to-large ophthalmology-adjacent company without a next-generation retinal asset, this round just repriced your acquisition options. A pre-Phase 3 VEGF/Ang-2 bispecific with head-to-head Phase 1b data against faricimab, now capitalized at $330 million with a coalition of crossover investors including sovereign wealth, pension capital, and multi-strategy funds, will not be a cheap target by Phase 3 interim readout. The oversubscription signals that demand for this asset exceeded supply of equity at current terms. That is a negotiating posture, not just a financing outcome.
The next signal to watch: the Phase 3 protocol design. Ollin announced trials commencing in H2 2026. Whether those studies are powered for superiority or non-inferiority against faricimab will tell you everything about what the investors actually believe the JADE data showed, and how aggressively the company intends to pursue a label claim that makes a commercial conversation with Roche’s retinal franchise unavoidable.
References
- PR Newswire — “Innovent’s Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing,” June 24, 2026
- Ollin Biosciences — “Final Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo) in Wet AMD and DME” (JADE study)
- PMC/NLM — “Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases”
- Research and Markets — “Diabetic Macular Edema Market Report & Forecast” (2024–2034)
- Dataintelo — “Wet Age Related Macular Degeneration (AMD) Market Research Report 2033”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
